Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02838628 · ClinicalTrials.gov registry record · Phase 2
Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp
A Phase 2 study, sponsored by Almirall, S.A..
- Completed
- Registry status
- Phase 2
- Development phase
- 168
- Enrollment target
NCT02838628 is a Phase 2 study that has completed, run by Almirall, S.A.. The registered enrollment target is 168 participants.
The verdict
NCT02838628, a Phase 2 study, has completed, sponsored by Almirall, S.A..
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 168 participants
- Enrollment target
Study Summary
In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
Interventions
- DRUG 50 mg of KX2-391 Ointment 1%
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 168 participants |
| Start Date | 2016-04-11 |
| Est. Completion | 2017-12-22 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02838628
The ClinicalTrials.gov registry entry for NCT02838628 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 168 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Almirall, S.A., which has 19 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which 50 mg of KX2-391 Ointment 1% is the first listed.
NCT02838628 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02838628 about?
NCT02838628 is a clinical study titled "Activity & Safety Study of KX2-391 Ointment in Participants With Actinic Keratosis on the Face or Scalp". In this study, the activity, safety, and pharmacokinetics (PK) of KX2-391 Ointment was evaluated in adult participants with a clinical diagnosis of stable, clinically typical actinic keratosis (AK) on the face or scalp.
What is the current status of trial NCT02838628?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 168 participants. The study started on 2016-04-11. Estimated completion is 2017-12-22.
What interventions are being tested in trial NCT02838628?
The interventions under investigation include: 50 mg of KX2-391 Ointment 1% (DRUG).
Who is sponsoring clinical trial NCT02838628?
This trial is sponsored by Almirall, S.A., which has 19 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.